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Background
In the current study, we tested the effects of sustained
cardiac proBNP gene delivery on blood pressure (BP),
cardiac function and remodeling in spontaneously
hypertensive rats (SHR).
Methods
We used the myocardium-tropic adeno-associated virus
serotype 9 (AAV9) vector to achieve continuously
enhanced cardiac rat proBNP expression. *p<0.05 vs
treated rats.
Results
In SHR, a single systemic administration of AAV9 vector
allowed longterm, cardiac BNP overexpression with an
increase in plasma BNP levels as compared with
untreated SHR (433.3±17 vs 60.6±15* pg/ml). This
further resulted in reductions in systolic (121±11 vs 184
±13* mm Hg) and diastolic (103±5 vs 148±24* mm Hg)
BP for nine months after injection as compared with
untreated SHR. Left ventricular (LV) thickness (1.87±0.1
vs 2.16±0.3* mm), LV end-systolic dimensions (3.96±0.3
vs 4.66±0.6* mm) and LV mass (0.4±0.01 vs 0.49±0.01*
gr) were reduced, while ejection fraction was increased
(83±2 vs 74±4* %) in BNP-treated compared to untreated
SHR. Circumferential systolic strain (-5.04±0.4 vs -3.74
±0.4* %) and strain rate of the early phase of diastole
(-4.57±2.1 vs -2.41±1.3 1/s) were improved in BNP-trea-
ted compared with controls. Importantly, the improve-
ment in cardiac function and structure also resulted in a
significant increase in survival (p<0.001 vs untreated
SHR). Non-cardiac overexpression of BNP, via AAV2
vector, was not associated with changes in plasma BNP
and BP in SHR. Nevertheless, normotensive Wistar rats
injected with AAV9 proBNP vector showed significantly
reduced heart/body weights (0.31± 0.1 vs 3.9±0.1* %)
four weeks after injection without BP reduction com-
pared to untreated rats.
Conclusion
AAV9 vector facilitates sustained cardiac proBNP overex-
pression improves both systolic and diastolic cardiac func-
tion in hypertensive heart disease. Long-term proBNP
delivery improved survival in SHR. The effects on cardiac
structure and function occurred independently of BP low-
ering effects in normotensive Wistar rats.
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